

November 22, 2022

To,
Dy. General Manager
Department of Corporate Services,
BSE Ltd.,
P. J. Towers, Dalal Street,
Fort, Mumbai – 400 001.

To,
The Manager – Listing,
The National Stock Exchange of India Ltd.,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051.

Ref: Scrip Code: 532296

Ref: Scrip Name: GLENMARK

Dear Sir,

Sub: Glenmark Pharmaceuticals reaches settlement agreement with Pfizer for Axitinib Tablets, 1 mg and 5 mg

With reference to the subject mentioned above, kindly find attached media release which is self-explanatory.

Request you to kindly take the same on record.

Thanking you,

Yours faithfully,
For Glenmark Pharmaceuticals Limited

Harish Kuber
Company Secretary & Compliance Officer

Encl: as above

Press Release

For Immediate Release

Glenmark Pharmaceuticals reaches settlement agreement with Pfizer for Axitinib Tablets, 1 mg and 5 mg

Mumbai, India and Mahwah, New Jersey, November 22, 2022 – Glenmark Pharmaceuticals Inc., USA (Glenmark) and Glenmark Pharmaceuticals Limited have reached a settlement agreement with Pfizer Inc., PF Prism C.V., and PF Prism IMB B.V. (Pfizer) for Axitinib Tablets, 1 mg and 5 mg, the generic version of their Inlyta^{®1} Tablets, 1 mg and 5 mg. Glenmark had previously announced it received tentative approval by the United States Food & Drug Administration (U.S. FDA) for their generic Axitinib Tablets, 1 mg and 5 mg on November 30, 2020.

According to IQVIA[™] sales data for the 12-month period ending September 2022, the Inlyta[®] Tablets, 1 mg and 5 mg market² achieved annual sales of approximately \$644.5 million*.

Glenmark's current portfolio consists of 177 products authorized for distribution in the U.S. marketplace and 47 ANDA's pending approval with the U.S. FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.

---End---

About Glenmark Pharmaceuticals Ltd

Glenmark Pharmaceuticals Ltd. (BSE: 532296 | NSE: GLENMARK) is an innovation-driven global pharmaceutical company with a presence across Specialty, Generics and OTC businesses. It focuses on the key therapeutic areas of respiratory, dermatology and oncology. The company has 10 world-class manufacturing facilities spread across 4 continents and operations in over 80 countries. Glenmark is ranked among the world's top 100 biopharmaceutical companies (Top 100 Companies Ranked by Pharmaceutical Sales, 2020, by In Vivo/Scrip 100) and among the world's top 50 companies in the off-patent sector (Top 50 Generics and Biosimilars Companies ranked by Sales, 2020, by Generics Bulletin/In Vivo). The company was listed on the Dow Jones Sustainability Index (DJSI), one of the world's most respected and widely accepted sustainability benchmarks, under the category of emerging markets (2021) for the fourth consecutive year. For more information, visit www.glenmarkpharma.com. LinkedIn (Glenmark Pharmaceuticals), Instagram ([glenmark_pharma](https://www.instagram.com/glenmark_pharma)).

For further information, please contact:

Udaykumar Murthy | Tel: +91 9960377617 | Email: corpcomm@glenmarkpharma.com

References:

¹All brand names and trademarks are the property of their respective owners.

²Market includes brand and all available therapeutic equivalents, which may include indications for which Glenmark is not tentatively approved.

*IQVIA[™] National Sales Perspectives: Retail & Non-Retail, September 2022